Last reviewed · How we verify
calcipotriol hydrate [Daivonex]
Calcipotriol is a vitamin D3 analog that binds to the vitamin D receptor to regulate skin cell differentiation and proliferation, reducing excessive keratinocyte growth.
Calcipotriol is a vitamin D3 analog that binds to the vitamin D receptor to regulate skin cell differentiation and proliferation, reducing excessive keratinocyte growth. Used for Plaque psoriasis, Psoriatic dermatitis.
At a glance
| Generic name | calcipotriol hydrate [Daivonex] |
|---|---|
| Sponsor | Hoffmann-La Roche |
| Drug class | Vitamin D3 analog |
| Target | Vitamin D receptor (VDR) |
| Modality | Small molecule |
| Therapeutic area | Dermatology |
| Phase | FDA-approved |
Mechanism of action
Calcipotriol acts as a selective agonist of the vitamin D receptor (VDR), which modulates gene expression involved in cell differentiation and immune regulation in the skin. By promoting normal keratinocyte maturation and reducing abnormal proliferation, it helps normalize the pathological skin changes seen in psoriasis and other hyperproliferative skin disorders.
Approved indications
- Plaque psoriasis
- Psoriatic dermatitis
Common side effects
- Skin irritation at application site
- Hypercalcemia (with systemic absorption)
- Pruritus
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- calcipotriol hydrate [Daivonex] CI brief — competitive landscape report
- calcipotriol hydrate [Daivonex] updates RSS · CI watch RSS
- Hoffmann-La Roche portfolio CI